Broadly neutralizing antibodies from human survivors target a conserved site in the ebola virus glycoprotein hr2-mper region

Nature Microbiology

Volumn 3, Issue 6, 2018, Pages 670-677

  Flyak, Andrew I ^a,g   Kuzmina, Natalia ^b,c   Murin, Charles D ^d   Bryan, Christopher ^e   Davidson, Edgar ^e   Gilchuk, Pavlo ^f   Gulka, Christopher P ^f   Ilinykh, Philipp A ^b,c   Shen, Xiaoli ^b,c   Huang, Kai ^b,c   Ramanathan, Palaniappan ^b,c   Turner, Hannah ^d   Fusco, Marnie L ^d   Lampley, Rebecca ^f   Kose, Nurgun ^f   King, Hannah ^f   Sapparapu, Gopal ^f   Doranz, Benjamin J ^e   Ksiazek, Thomas G ^b,c   Wright, David W ^f   Saphire, Erica Ollmann ^d   Ward, Andrew B ^d   Bukreyev, Alexander ^b,c   Crowe, James E ^a,f   more..

^a VANDERBILT UNIVERSITY   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c Galveston National Laboratory   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e Integral Molecular Inc   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g California Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; EPITOPE; NEUTRALIZING ANTIBODY; PEPTIDE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS GLYCOPROTEIN HR2 MPER; MEMBRANE PROTEIN; PROTEIN BINDING; VIRAL PROTEIN; VIRUS ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DETECTION; ARTICLE; BUNDIBUGYO VIRUS; CONTROLLED STUDY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; FEMALE; GUINEA PIG; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; LEPORIDAE; MALE; MUSTELA PUTORIUS FURO; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; STRUCTURE ANALYSIS; SURVIVOR; ANIMAL; BINDING SITE; CHEMISTRY; CHLOROCEBUS AETHIOPS; CROSS REACTION; DRUG EFFECT; IMMUNOLOGY; METABOLISM; MOLECULAR MODEL; MOUSE; VERO CELL LINE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BINDING SITES; CERCOPITHECUS AETHIOPS; CROSS REACTIONS; EBOLAVIRUS; EPITOPES; FERRETS; GUINEA PIGS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MODELS, MOLECULAR; PROTEIN BINDING; RABBITS; VERO CELLS; VIRAL PROTEINS;

EID: 85046541781     PISSN: None     EISSN: 20585276     Source Type: Journal    
DOI: 10.1038/s41564-018-0157-z     Document Type: Article

References (41)

1. Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47-53 (2014).
2. Lyon, G. M. et al. Clinical care of two patients with Ebola virus disease in the United States. N. Engl. J. Med. 371, 2402-2409 (2014).
3. Qiu, X. et al. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin. Immunol. 141, 218-227 (2011).
4. Qiu, X. et al. Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med. 4, 138ra81 (2012).
5. Olinger, G. G. Jr et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc. Natl Acad. Sci. USA 109, 18030-18035 (2012).
6. Wilson, J. A. et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287, 1664-1666 (2000).
7. Murin, C. D. et al. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc. Natl Acad. Sci. USA 111, 17182-17187 (2014).
8. Davidson, E. et al. Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies. J. Virol. 89, 10982-10992 (2015).
9. Flyak, A. I. et al. Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection. Cell 164, 392-405 (2016).
10. Zhao, Y. et al. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature 535, 169-172 (2016).
11. Weissenhorn, W., Carfi, A., Lee, K. H., Skehel, J. J. & Wiley, D. C. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol. Cell 2, 605-616 (1998).
12. Bornholdt, Z. A. et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science 351, 1078-1083 (2016).
13. Wec, A. Z. et al. Antibodies from a human survivor define sites of vulnerability for broad protection against ebolaviruses. Cell 169, 878-890 (2017).
14. Yu, J. S. et al. Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor. J. Virol. Methods 137, 219-228 (2006).
15. Cross, R. W. et al. The domestic ferret (Mustela putorius furo) as a lethal infection model for 3 species of Ebolavirus. J. Infect. Dis. 214, 565-569 (2016).
16. Kozak, R. et al. Ferrets infected with Bundibugyo virus or Ebola virus recapitulate important aspects of human filovirus disease. J. Virol. 90, 9209-9223 (2016).
17. Ilinykh, P. A. et al. Chimeric filoviruses for identification and characterization of monoclonal antibodies. J. Virol. 90, 3890-3901 (2016).
18. Malashkevich, V. N. et al. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-Å resolution. Proc. Natl Acad. Sci. USA 96, 2662-2667 (1999).
19. Lee, J. et al. Structure of the Ebola virus envelope protein MPER/TM domain and its interaction with the fusion loop explains their fusion activity. Proc. Natl Acad. Sci. USA 114, E7987-E7996 (2017).
20. Zhao, X. et al. Immunization-elicited broadly protective antibody reveals ebolavirus fusion loop as a site of vulnerability. Cell 169, 891-904 (2017).
21. Muster, T. et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67, 6642-6647 (1993).
22. Zwick, M. B. et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75, 10892-10905 (2001).
23. Montero, M., van Houten, N. E., Wang, X. & Scott, J. K. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev. 72, 54-84 (2008).
24. Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251 (2009).
25. Sui, J. et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265-273 (2009).
26. Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856 (2011).
27. Flyak, A. I. et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 160, 893-903 (2015).
28. Lee, J. E. et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454, 177-182 (2008).
29. Lee, J. E. et al. Techniques and tactics used in determining the structure of the trimeric ebolavirus glycoprotein. Acta Crystallogr. D Biol. Crystallogr. 65, 1162-1180 (2009).
30. Towner, J. S. et al. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-Throughput antiviral drug screening. Virology 332, 20-27 (2005).
31. Lubaki, N. M. et al. The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains. J. Virol. 87, 7471-7485 (2013).
32. Suloway, C. et al. Automated molecular microscopy: The new Leginon system. J. Struct. Biol. 151, 41-60 (2005).
33. Lander, G. C. et al. Appion: An integrated, database-driven pipeline to facilitate EM image processing. J. Struct. Biol. 166, 95-102 (2009).
34. Voss, N. R., Yoshioka, C. K., Radermacher, M., Potter, C. S. & Carragher, B. DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy. J. Struct. Biol. 166, 205-213 (2009).
35. van Heel, M., Harauz, G., Orlova, E. V., Schmidt, R. & Schatz, M. A new generation of the IMAGIC image processing system. J. Struct. Biol. 116, 17-24 (1996).
36. Davidson, E. & Doranz, B. J. A high-Throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes. Immunology 143, 13-20 (2014).
37. Bodanszky, M. & Bodanszky, A. The Practice of Peptide Synthesis 2nd edn (Springer, Berlin, 1994).
38. Grant, G. A. Synthetic Peptides: A User's Guide (W.H. Freeman, New York, 1992).
39. Fields, G. B. & Noble, R. L. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J. Pept. Protein Res. 35, 161-214 (1990).
40. Stuber, W., Knolle, J. & Breipohl, G. Synthesis of peptide amides by Fmoc-solid-phase peptide synthesis and acid labile anchor groups. Int J. Pept. Protein Res. 34, 215-221 (1989).
41. Atherton, E., Cameron, L. R. & Sheppard, R. C. Peptide synthesis: part 10. Use of pentafluorophenyl esters of fluorenylmethoxycarbonyl amino acids in solid phase peptide synthesis. Tetrahedron 44, 843-857 (1988).